# A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

> **NCT06434610** · PHASE2 · RECRUITING · sponsor: **Shanghai Jiaolian Drug Research and Development Co., Ltd** · enrollment: 90 (estimated)

## Conditions studied

- Platinum-resistant Recurrent Ovarian Cancer

## Interventions

- **DRUG:** B013
- **DRUG:** Paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06434610
- **Lead sponsor:** Shanghai Jiaolian Drug Research and Development Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06434610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06434610, "A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06434610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*